Terms ending in 2038
Every in-force patent on Cellectis's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,836,998 | Cells for Immunotherapy Engineered for Targeting Antigen Present Both on Immune Cells and Pathological Cells In force · High confidence | Cellectis | In force | High confidence | |
| US 12,133,867 | Universal ANTI-CD22 Chimeric Antigen Receptor Engineered Immune Cells In force · High confidence | Cellectis S.A. | In force | High confidence | |
| US 11,186,824 | Methods for Engineering Allogeneic T Cell to Increase Their Persistence And/Or Engraftment into Patients In force · High confidence | Cellectis | In force | High confidence | |
| US 11,820,996 | Method for Generating T-Cells Compatible for Allogenic Transplantation In force · High confidence | Cellectis | In force | High confidence | |
| US 11,479,782 | Alfalfa with Reduced Lignin Composition In force · High confidence | Cellectis | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.